High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin

Journal of Substance Abuse Treatment

Volumn 38, Issue 4, 2010, Pages 338-345

  Waizmann, Michael ^a   Ackermann, Grit ^a  

^a Medcenter Leipzig   (Germany)

Author keywords

Directly observed therapy; HCV; Maintenance therapy; Treatment

Indexed keywords

BUPRENORPHINE; CITALOPRAM; METHADONE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIRECTLY OBSERVED THERAPY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; MALE; NONHUMAN; OPIATE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; VIRUS GENE;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; BUPRENORPHINE; CITALOPRAM; DEPRESSION; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; METHADONE; MIDDLE AGED; NARCOTICS; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952224815     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2010.02.002     Document Type: Article

References (39)

1. Aceijas C., Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. International Journal on Drug Policy 2007, 18:352-358.
2. Altice F.L., Maru D.S., Bruce R.D., Springer S.A., Friedland G.H. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: A prospective, randomized, controlled trial. Clinical Infectious Diseases 2007, 45:770-778.
3. Amon J.J., Garfein R.S., Ahdieh-Grant L., Armstrong G.L., Ouellet L.J., Latka M.H., et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clinical Infectious Diseases 2008, 46:1852-1858.
4. Anagnostou O., Manolakopoulos S., Deutsch M., Tiniakou E., Giannaris M., Papatheodoridis G. Drug users with chronic hepatitis C who are adherent to antiviral treatment will finally benefit from therapy. Gastroenterology 2008, 134:A775.
5. Belfiori B., Ciliegi P., Chiodera A., Bacosi D., Tosti A., Baldelli F., et al. Peginterferon plus ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. Digestive and Liver Disease 2009, 41:303-307.
6. Bonkovsky H.L., Tice A.D., Yapp R.G., Bodenheimer H.C., Monto A., Rossi S.J., et al. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: Randomized comparison of direct observed therapy and self-administration. American Journal of Gastroenterology 2008, 103:2757-2765.
7. Chossegros P., Mélin P., Hézode C., Bourlière M., Pol S., Fhima A., et al. A French prospective observational study of the treatment of chronic hepatitis C in drug abusers. Gastroentérologie Clinique et Biologique 2008, 32:850-885.
8. Ciaccio A., Ferraro D., Alaimo G., Maggio A.A., Craxi A., Almasio P.L. Feasibility of combination therapy for chronic hepatitis C in IVDU in the framework of a heroin detoxification protocol. Hepatology 2007, 46:393A-394A.
9. Conway B., Prasad J., Reynolds R., Farley J., Jones M., Jutha S., et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clinical Infectious Diseases 2004, 38:S402-S408.
10. de Bie J., Robaeys G., Buntinx F. Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU): Guidelines for clinical practice. Acta Gastroenterologica Belg 2005, 68:68-80.
11. Dieperink E., Ho S.B., Thuras P., Willenbring M.L. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003, 44:104-112.
12. Dore G.J., Thomas D.L. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Seminars in Liver Disease, 25, 18-32. Journal on Drug Policy 2005, 18:341-351.
13. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 2002, 347:975-982.
14. Grebely J., Genoway K., Khara M., Duncan F., Viljoen M., Elliott D., et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. International Journal on Drug Policy 2007, 18:437-443.
15. Hadziyannis S.J., Sette H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine 2004, 140:346-355.
16. Hagan H., Des Jarlais D.C., Stern R., Lelutiu-Weinberger C., Scheinmann R., Strauss S., et al. HCV synthesis project: Preliminary analyses of HCV prevalence in relation to age and duration of injection. International Journal on Drug Policy 2007, 18:341-351.
17. Hauser P., Khosla J., Aurora H., Laurin J., Kling M.A., Hill J., et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry 2002, 7:942-947.
18. Krook A.L., Stokka D., Heger B., Nygaard E. Hepatitis C treatment of opioid dependants receiving maintenance treatment: Results of a Norwegian pilot study. European Addiction Research 2007, 13:216-221.
19. Litwin A.H., Soloway I., Gourevitch M.N. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities. Clinical Infectious Diseases 2005, 40:S339-345.
20. Loftis J.M., Socherman R.E., Howell C.D., Whitehead A.J., Hill J.A., Dominitz J.A., et al. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neuroscience Letters 2004, 365:87-91.
21. Lucas G.M., Mullen B.A., Weidle P.J., Hader S., McCaul M.E., Moore R.D. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clinical Infectious Diseases 2006, 42:1628-1635.
22. Lucas G.M., Weidle P.J., Hader S., Moore R.D. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: A nonrandomized comparative study. Clinical Infectious Diseases 2004, 38:S409-S413.
23. Martín-Santos R., Díez-Quevedo C., Castellví P., Navinés R., Miquel M., Masnou H. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Alimentary Pharmacology and Therapeutics 2008, 27:257-265.
24. Maru D.S., Bruce R.D., Walton M., Mezger J.A., Springer S.A., Shield D., et al. Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. AIDS and Behaviour 2008, 12:284-293.
25. Mauss S., Berger F., Goelz J., Jacob B., Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004, 40:120-124.
26. McHutchison J.G., Manns M., Patel K., Poynard T., Lindsay K.L., Trepo C., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069.
27. Morasco B.J., Rifai M.A., Loftis J.M., Indest D.W., Moles J.K., Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. Journal of Affective Disorders 2007, 103:83-90.
28. NIH Consensus Statement on Management of Hepatitis C: 2002 NIH Consensus State-of-the-Science Statements 2002, Vol. 19:1-46.
29. Pellicelli A.M., Barbaro G., Barbarini G., Soccorsi F. Management of chronic hepatitis in drug addicts: A systematic review. Clinical Therapeutics 2008, 159:41-49. CLEO Group.
30. Raison C.L., Woolwine B.J., Demetrashvili M.F., Borisov A.S., Weinreib R., Staab J., et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary Pharmacology and Therapeutics 2007, 25:1163-1174.
31. Robaeys G., Van Vlierberghe H., Matheï C., Van Ranst M., Bruckers L., Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. European Journal of Gastroenterology and Hepatology 2006, 18:159-166.
32. Schaefer M., Schmidt F., Folwaczny C., Lorenz R., Martin G., Schindlbeck N., et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003, 37:443-451.
33. Schaefer M., Schmidt F., Horn M., Schmid-Wendtner M.H., Volkenandt M. Depression during treatment with interferon alpha. Psychosomatics 2004, 45:176.
34. Schaefer M., Schwaiger M., Garkisch A.S., Pich M., Hinzpeter A., Uebelhack R., et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. Journal of Hepatology 2005, 42:793-798.
35. Smith-Rohrberg D., Mezger J., Walton M., Bruce R.D., Altice F.L. Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. Acquired Immune Deficiency Syndrome 2006, 43:S48-53.
36. Strader D.B., Wright T., Thomas D.L., Seeff L.B. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
37. Sulkowski M.S. Anemia in the treatment of hepatitis C virus infection. Clinical Infectious Diseases 2003, 37:S315-322.
38. Sylvestre D.L., Clements B.J. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. European Journal of Gastroenterology and Hepatology 2007, 19:741-747.
39. van Thiel D.H., Anantharaju A., Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. American Journal of Gastroenterology 2003, 98:2281-2288.